SCHEMBL417732

SCHEMBL417732

Cc1ccc(SCCCC(=O)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.70
HPGD P15428 7/20 0.53
KDM4E B2RXH2 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995027 0.95 ALDH1A1 (0.62) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL21102358 0.93 ALDH1A1 (0.61) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL21102172 0.93 ALDH1A1 (0.61) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL909499 0.89 HPGD (0.60) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL17131550 0.85 HPGD (0.53) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL20578188 0.84 HPGD (0.51) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL416482 0.83 ALDH1A1 (0.72) ALDH1A1CYP1A2CYP3A4CYP2C19NPC1
SCHEMBL1932191 0.82 ALDH1A1 (1.00) ALDH1A1HPGDKDM4ECYP1A2CYP3A4
SCHEMBL2213968 0.82 ALDH1A1 (0.66) ALDH1A1HPGDNPC1RAB9AL3MBTL1
SCHEMBL9775156 0.82 RAB9A (0.70) ALDH1A1HPGDCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3634948-B1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INST NAT SANTE RECH MED (FR) 2025-09-17 EP disclosed
EP-3634949-B1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INST NAT SANTE RECH MED (FR) 2025-03-19 EP disclosed
US-11795144-B2 Inhibitors of RAC1 and uses thereof for treating cancers INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-10-24 US disclosed
US-11607419-B2 Inhibitors of RAC1 and uses thereof for inducing bronchodilatation INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-03-21 US disclosed
WO-2018224563-A9 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2021-04-22 WO disclosed
US-20210077508-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION NANTES UNIVERSITE (FR) 2021-03-18 US disclosed
EP-3634949-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2020-04-15 EP disclosed
EP-3634948-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) 2020-04-15 EP disclosed
US-20200095199-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS NANTES UNIVERSITE (FR) 2020-03-26 US disclosed
EP-2046736-B1 ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2019-06-12 EP disclosed
WO-2018224560-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-13 WO disclosed
WO-2018224563-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-13 WO disclosed
EP-3412651-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-12 EP disclosed
EP-3412652-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2018-12-12 EP disclosed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795144-B2 Inhibitors of RAC1 and uses thereof for treating cancers RAC1, KRAS, CYRIB ALDH1A1 2069/4885HPGD 1309/4885KDM4E 4341/4885
US-11607419-B2 Inhibitors of RAC1 and uses thereof for inducing bronchodilatation RAC1, CYRIB, ARHGDIB ALDH1A1 2264/4885HPGD 550/4885KDM4E 4687/4885
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 ALDH1A1 455/4885HPGD 2716/4885KDM4E 674/4885
US-20210077508-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION RAC1, CYRIB, ARHGDIB ALDH1A1 2264/4885HPGD 550/4885KDM4E 4687/4885
US-20200095199-A1 INHIBITORS OF RAC1 AND USES THEREOF FOR TREATING CANCERS RAC1, KRAS, CYRIB ALDH1A1 2069/4885HPGD 1309/4885KDM4E 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.